SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

COMPLETION OF PROPOSED TRANSACTIONS:

A. PROPOSED CONVERSION OF LOAN FROM CATERINE LIMITED INTO NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY ("SHARES"); AND

B. PROPOSED PLACEMENT OF AN AGGREGATE OF 19,748,000 NEW SHARES AT A PLACEMENT PRICE OF S$0.035 PER SHARE TO CERTAIN SUBSCRIBERS

(COLLECTIVELY, THE "PROPOSED TRANSACTIONS")

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") refers to the Company's announcements dated 30 September 2025 and 9 October 2025 (collectively, the "**Announcements**") relating to the Company's entry into, and the receipt of listing and quotation notice from the SGX-ST in relation to, the Proposed Transactions:

(i) the proposed conversion of the Loan from Caterine Limited into 149,726,000 new ordinary shares in the capital of the Company ("**Shares**") (the "**Debt Conversion Shares**") (the "**Caterine Debt Conversion**"); and

(ii) the Proposed Placement of an aggregate of 19,748,000 new Shares ("**Placement Shares**") at a placement price of S$0.035 per Share to certain subscribers.

The Board wishes to announce that the completion of the Proposed Transactions has taken place today in accordance with the terms and conditions set out in the Debt Conversion Deed and the Subscription Agreements, respectively. Accordingly, the Company has allotted and issued an aggregate of 169,474,000 new Shares today, of which such new Shares which are issued in scripless form will be credited on or around 16 October 2025, as below:

(i) 149,726,000 Debt Conversion Shares to Caterine Limited pursuant to the Caterine Debt Conversion; and

(ii) an aggregate of 19,748,000 Placement Shares to the respective Subscribers via the Nominees specified below:

S/N	Nominee	Number of Placement Shares
PSG Agreement		
1.	PHEIM ASEAN All-Cap Equity Fund	4,185,000
2.	PHEIM VCC – PHEIM Emerging Asia Ex-Japan Balanced Fund	2,028,000
	Sub-Total (PHEIM SG):	**6,213,000**

PMY Agreement		
3.	Thong Thye Chiang Sdn Bhd	457,000
4.	Thong Thye Chiang Realty Sdn Bhd	202,000
5.	PHEIM Emerging Companies Balanced Fund	714,000
6.	Dana Makmur PHEIM	8,771,000
7.	Benta Wawasan Sdn Bhd	1,028,000
8.	German-Malaysian Institute	754,000
9.	PHEIM Asia Ex-Japan Fund	320,000
10.	PHEIM Asia Ex-Japan Islamic Fund	705,000
11.	Saham Sabah Bhd	297,000
	Sub-Total (PHEIM MY):	**13,248,000**
PIAM Agreement		
12.	PHEIM Global ESG Islamic Fund	182,000
13.	PHEIM Asean Islamic Fund	105,000
	Sub-Total (PHEIM IAM):	**287,000**
	TOTAL:	**19,748,000**

The Debt Conversion Shares and Placement Shares will, when allotted and issued, be credited as fully-paid Shares free from any and all encumbrances and rank *pari passu* in all respects with and carry all rights similar to the existing issued Shares, except that they will not rank for any dividend, right, allotment or other distributions the record date for which falls on or before the date of issue of the Debt Conversion Shares and Placement Shares.

Following the completion of the Proposed Transactions, the total number of Shares in the Company has increased from 1,062,020,642 Shares to 1,231,494,642 Shares.

The Debt Conversion Shares and Placement Shares are expected to be listed and quoted on the Catalist of the SGX-ST on or around 17 October 2025, and trading of the Debt Conversion Shares and Placement Shares is expected to commence with effect from 9.00 a.m. on the same date.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
15 October 2025

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.